Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 27
---
'>USE OF PROCEEDS</div>

We will not receive any of
the proceeds from the sale of Depositary Shares offered by the Selling Shareholder. In addition, we will not receive any proceeds from
the issuance or sale of the Commitment Shares if issued to the Selling Shareholder to release the Company of its liability to pay the
Commitment Fee. We may receive up to $35.0 million in aggregate gross proceeds from the Selling Shareholder under the Purchase Agreement
in connection with sales of our Depositary Shares to the Selling Shareholder pursuant to the Purchase Agreement after the date of this
prospectus. However, the actual proceeds may be less than this amount depending on the number of Depositary Shares sold and the price
at which the Depositary Shares are sold.

We intend to use any net proceeds
that we receive under the Purchase Agreement to fund our development programs, for working capital and other general corporate purposes.

The expected use of the net
proceeds from the offering represents our intentions based upon our current plans and business conditions, which could change in the future
as our plans and business conditions evolve. The amounts and timing of our actual expenditures depend on numerous factors, including the
ongoing status of and results from our clinical trials and other studies, the progress of our preclinical development efforts and any
unforeseen cash needs. As a result, our management will have broad discretion in applying the net proceeds of the offerings.

Pending the uses described
above, we plan to invest the net proceeds from this offering in short-term, interest-bearing investments.

| 18 |

<div align='center'>DIVIDEND POLICY</div>

Since
inception, we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on
our Ordinary Shares or the Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings
to fund the development and expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit
in the foreseeable future only if the Ordinary Shares and Depositary Shares appreciate in value.

Any
determination to pay dividends in the future would be at the discretion of our Board of Directors and will depend upon our results of
operations, cash requirements, financial condition, contractual restrictions, and any future debt agreements and is subject to compliance
with applicable laws, including the United Kingdom Companies Act of 2006, or the Companies Act, which requires English companies to have
profits